The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2013 by Meir Medical Center.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Meir Medical Center Identifier:
First received: March 10, 2013
Last updated: April 8, 2015
Last verified: October 2013
We hypothesized that the multi-disciplinary assessment of interstitial lung disease patients would lead to a more accurate diagnosis and consequently alterations in treatment regimens that may lead to improved outcomes.

Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis
Connective Tissue Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

Resource links provided by NLM:

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • The number of patients with collagen related pulmonary fibrosis that are diagnosed by Rheumatologists compared to Pulmonologists. [ Time Frame: two years ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: May 2013
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
60 patients that will refer to the pulmonary outpatient or inpatients department for evaluation due to ILD will be included

Inclusion Criteria:

  • Age above 18 years old
  • ILD according to ATS/ERS guidelines
  • Signed inform consent

Exclusion Criteria:

  • Previous lung surgery
  • Other significant systemic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01809574

Contact: David Shitrit, Dr. 097471556

Meir Medical Center Recruiting
Kfar Saba, Israel, 972
Contact: David Shitrit, Dr    09-7471556   
Sponsors and Collaborators
Meir Medical Center
Principal Investigator: David Shitrit, Dr Head of Pulmonary departmant, Meir Medical Center.
  More Information

Responsible Party: Meir Medical Center Identifier: NCT01809574     History of Changes
Other Study ID Numbers: 225-12-MMC 
Study First Received: March 10, 2013
Last Updated: April 8, 2015
Health Authority: Israel: Ethics Commission

Keywords provided by Meir Medical Center:
Interstitial lung disease
Idiopathic pulmonary fibrosis
Connective tissue disease

Additional relevant MeSH terms:
Connective Tissue Diseases
Idiopathic Interstitial Pneumonias
Idiopathic Pulmonary Fibrosis
Lung Diseases
Lung Diseases, Interstitial
Pulmonary Fibrosis
Respiratory Tract Diseases processed this record on May 24, 2016